• Routine and standard quantitative and qualitative assessment of plaque changes and growth [ Time Frame: Weekly ] [ Designated as safety issue: No ]
  
• Severity Index, clinically described as to redness, flaking and thickness on a total scale of 9 [ Time Frame: Weekly ] [ Designated as safety issue: No ]
  

• Impacts of Events Scale (IES) [ Time Frame: Once - at the initial start of the study ] [ Designated as safety issue: No ]
  
• Psoriasis Life Stress Inventory) (PLSI) [ Time Frame: Weekly ] [ Designated as safety issue: No ]
  
• Hassles Scale [ Time Frame: Weekly ] [ Designated as safety issue: No ]
  
• Interpersonal Support Evaluation List (ISEL) [ Time Frame: Once - at the intial start of the study ] [ Designated as safety issue: No ]
  

The lack of scientific attention devoted to the placebo effect as a phenomenon in its own right probably reflects the paucity of theoretical positions within which to organize the existing data and design new research. This research addresses the clinical significance of behavior-immune system interactions.

This study will capitalize on conditioned immunosuppressive responses to reduce the cumulative amount of corticosteroid medication used in the treatment of psoriasis. We will continue to treat patients with steroid, but will shift experimental patients from their current schedule of continuous reinforcement (active drug whenever medication is applied) to a partial schedule of reinforcement (active drug a percentage of the time and placebo alone at other times). To equate amount of medication, we will treat another group of patients with a reduced dose of steroid in a standard treatment regimen (continuous schedule of reinforcement).

We hypothesize that, holding cumulative dose constant, a partial schedule of reinforcement will enable patients to be maintained on lower cumulative amounts of corticosteroid than patients treated under a continuous schedule of active drug. This is the first attempt to adopt conditioning principles and use schedules of reinforcement to design regimens of drug therapy. If proven effective, this new approach to pharmacotherapy and placebo effects is likely to stimulate new interdisciplinary research in neuropharmacology and behavioral pharmacology for the treatment of autoimmune disorders and a variety of other chronic diseases.

Inclusion Criteria:

• Psoriasis patients with mild to moderate lesions who are able to attend weekly clinic visits at either the University of Rochester School of Medicine and Dentistry in Rochester, NY, or Stanford University in Palo Alto, CA.
• Patients must be in good health (as determined by prescreening examination).
• Patients must not be using systemic treatment (for example, oral medications) or intralesional, UV, or topical therapies except bland emollients for at least 2 weeks before the start date of the study.
• Patients must have chronic, stable plaque psoriasis with a score of greater than or equal to 7 on a routine 9-point Severity Index.

Exclusion Criteria:

• Use of immunosuppressive medication within the past 2 months.
• Pregnant or sexually active women who do not use contraceptives.
• Patients who cannot be monitored regularly.
• History of allergy to corticosteroid or other study ointment components.
• Patients who have more than 10 percent of body surface area covered by psoriatic lesions.